NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

DNA degradation test predicts success in whole-genome amplification from diverse clinical samples.

Author(s): Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM

Publication: J Mol Diagn, 2007, Vol. 9, Page 441-51

PubMed ID: 17690213 PubMed Review Paper? No

Suggested by: ISBER


Purpose of Paper

The purpose of this paper was to compare methods to predict real-time PCR success after restriction and circularization-aided rolling circle amplification (RCA-RCA) whole genome amplification (WGA) of DNA from stored formalin-fixed and paraffin-embedded (FFPE) glioblastomas and colorectal carcinomas and from circulating plasma DNA.

Conclusion of Paper

DNA gliomas/glioblastomas stored for 5-7 years generally yielded more intact DNA than the colorectal carcinomas stored for 10-12 years. DNA degradation, as detected by electrophoresis, did not correspond to real-time PCR success after RCA-RCA amplification, but multiplex PCR success, evaluated with denaturing high-performance liquid chromatography (dHPLC) instead of electrophoresis, was a better indicator of subsequent real-time PCR success after RCA-RCA amplification.

Studies

  1. Study Purpose

    The purpose of this study was to determine the effects of storage and specimen type on DNA integrity and real-time PCR success after RCA-RCA WGA. DNA was extracted from snap-frozen and xylene-deparaffinized, proteinase K-digested FFPE specimens using DNEasy. Plasma DNA was obtained using QIAamp MinElute.

    Summary of Findings:

    DNA from 13 of the 16 gliomas stored for 5-7 years was intact as determined by electrophoresis and multiplex PCR. The remaining 3 specimens showed weakened amplification of products longer than 100 bp. After excluding the 3 specimens that showed degradation, all gliomas stored 5-7 years allowed for real-time PCR amplification after whole genome RCA-RCA amplification of at least 18 of the 20 genes tested. DNA from the colorectal carcinomas stored for 10-12 years was generally degraded, and only 1 of the 12 specimens allowed for equal amplification of all 4 multiplex PCR products. After RCA-RCA amplification, 2 of the 12 colorectal specimens allowed for real-time PCR amplification of all 20 genes. The remaining 10 RCA-RCA amplified colorectal specimens allowed for real-time PCR amplification of 4-18 of the 20 genes. Importantly, DNA degradation, as determined by electrophoresis, did not correspond to real-time PCR success after RCA-RCA amplification, but multiplex PCR success, evaluated with dHPLC instead of electrophoresis, was a better, but still not perfect, indicator of subsequent real-time PCR success after RCA-RCA amplification. Multiplex PCR dHPLC was able to predict subsequent real-time PCR success after RCA-RCA amplification from plasma-circulating DNA.

    Biospecimens
    Preservative Types
    • Formalin
    • Frozen
    Diagnoses:
    • Neoplastic - Carcinoma
    • Neoplastic - Other
    Platform:
    AnalyteTechnology Platform
    DNA Electrophoresis
    DNA Whole genome amplification
    DNA PCR
    DNA HPLC
    DNA Real-time qPCR
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Storage Storage duration 5-7 years
    10-12 years
    Biospecimen Acquisition Biospecimen location Glioma
    Glioblastoma
    Colorectal
    Plasma
    Biospecimen Preservation Type of fixation/preservation Formalin (buffered)
    Snap frozen
    PCR Specific Technology platform Electrophoresis
    Real-time PCR
    PCR Specific Length of gene fragment 105 bp
    236 bp
    299 bp
    411 bp
    PCR Specific Targeted nucleic acid GAPDH
    PCR Specific Detection method Electrophoresis with ethidium bromide
    dHPLC

You Recently Viewed  

News and Announcements

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • Most Popular SOPs in March 2024

  • New SOPs Available

  • More...